Document is current
Any future updates will be listed below
-
Authors
O’Reilly, Eileen M. https://orcid.org/0000-0002-8076-9199
- License Information
-
More Information
Article History
First Online: 9 January 2026
Competing interests
: E.M.O. reports research funding to institution from Genentech/Roche, BioNTech, AstraZeneca, Arcus, Elicio Therapeutics, Parker Institute, NIH/NCI, Digestive Care, Break Through Cancer, Agenus, Amgen and Revolution Medicines; consulting/data and safety monitoring board, uncompensated from Arcus, Amgen, AstraZeneca, Ability Pharma, Alligator BioSciences, Pfizer, Agenus, BioNTech, Ipsen, Ikena, Merck, Immuneering, Moma Therapeutics, Novartis, Astellas, BMS, Revolution Medicines, Regeneron and Tango Therapeutics; travel expenses for BioNTech and Arcus; and other for American Association of Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Imedex, Research To Practice, Stand Up To Cancer (SU2C) and NIH/NCI Cancer Center Support Grant/Core Grant P30 CA008748 and NCI/NIH P50 CA257881-01A1.
